ATE353337T1 - Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet - Google Patents

Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet

Info

Publication number
ATE353337T1
ATE353337T1 AT97927563T AT97927563T ATE353337T1 AT E353337 T1 ATE353337 T1 AT E353337T1 AT 97927563 T AT97927563 T AT 97927563T AT 97927563 T AT97927563 T AT 97927563T AT E353337 T1 ATE353337 T1 AT E353337T1
Authority
AT
Austria
Prior art keywords
adhesin
blood group
protein
helicobacter pylori
pylori
Prior art date
Application number
AT97927563T
Other languages
English (en)
Inventor
Thomas Boren
Anna Arnqvist
Staffan Normark
Dag Ilver
Lennart Huddinge Hammarstroem
Original Assignee
Thomas Boren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9602287A external-priority patent/SE9602287D0/xx
Priority claimed from SE9701014A external-priority patent/SE9701014D0/xx
Application filed by Thomas Boren filed Critical Thomas Boren
Application granted granted Critical
Publication of ATE353337T1 publication Critical patent/ATE353337T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT97927563T 1996-06-10 1997-06-10 Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet ATE353337T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9602287A SE9602287D0 (sv) 1996-06-10 1996-06-10 Novel protein and methods for its use
SE9701014A SE9701014D0 (sv) 1997-03-19 1997-03-19 Novel polynucleotides and methods for their use

Publications (1)

Publication Number Publication Date
ATE353337T1 true ATE353337T1 (de) 2007-02-15

Family

ID=26662671

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927563T ATE353337T1 (de) 1996-06-10 1997-06-10 Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet

Country Status (10)

Country Link
US (3) US6709656B1 (de)
EP (1) EP0909272B1 (de)
JP (1) JP4112011B2 (de)
AT (1) ATE353337T1 (de)
AU (1) AU726429B2 (de)
CA (1) CA2257826C (de)
DE (1) DE69737323T2 (de)
ES (1) ES2281914T3 (de)
NZ (1) NZ333250A (de)
WO (1) WO1997047646A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4112011B2 (ja) * 1996-06-10 2008-07-02 トーマス、ボレン Ｈｅｌｉｃｏｂａｃｔｅｒ ｐｙｌｏｒｉアドヘシン結合型抗原
US6410719B1 (en) * 1996-06-10 2002-06-25 Thomas Boren Blood group antigen binding protein and corresponding agents
AU4718999A (en) * 1998-06-26 2000-01-17 American Cyanamid Company Novel antigens of (helicobacter pylori)
SE9904581D0 (sv) * 1999-12-15 1999-12-15 A & Science Invest Ab A novel helicobacter pylori-binding substance and use thereof
WO2002066502A1 (en) * 2001-02-21 2002-08-29 Boren Thomas Helicobacter pylori sialic acid binding adhesin, saba and saba - gene
SE0103695D0 (sv) 2001-11-07 2001-11-07 Thomas Boren A novel non-antibiotic strategy against OGIP infections based on a cereal product
US20040126811A1 (en) * 2002-02-21 2004-07-01 Thomas Boren Helicobacter pylori sialic acid binding adhesin, saba and saba-gene
US7326770B2 (en) * 2004-01-22 2008-02-05 Neose Technologies, Inc. H. pylori fucosyltransferases
GB2427194A (en) * 2005-06-16 2006-12-20 Domantis Ltd Single domain Helicobacter pylori adhesin antibodies
US8025880B2 (en) * 2007-03-01 2011-09-27 Helicure Ab Immunoglobulin against Helicobacter pylori
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN113846080B (zh) * 2021-09-06 2022-06-28 尤丽康（江苏）生物医药有限公司 幽门螺杆菌复合抗原、抗体、制备方法及应用
WO2024213778A2 (en) 2023-04-12 2024-10-17 Boren Thomas Methods for preventing the development of a gastric disease associated with helicobacter pylori infection without eradicating the infection and for the assessment of the risk of developing such disease

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
DK219084D0 (da) * 1984-05-02 1984-05-02 Frederik Carl Peter Lindberg Antigen
JP3096305B2 (ja) 1990-07-17 2000-10-10 ボード オブ リージェンツ オブ ザ ユニバーシティ オブ オクラホマ Ｇｍｐ―１４０に対する糖タンパク質リガンド
US5258178A (en) * 1990-07-30 1993-11-02 Abbott Laboratories Method and product for the treatment of gastric disease
DE4139840B4 (de) * 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
US5567594A (en) * 1991-04-26 1996-10-22 Enteron, L.P. Methods and compositions for the detection and treatment of diseases associated with antigens of microorganisms
US5262156A (en) * 1991-08-12 1993-11-16 Hycor Biomedical, Inc. Antigenic compositions and their use for the detection of Helicobacter pylori
US5258177A (en) * 1991-12-10 1993-11-02 Alpha Therapeutic Corporation IgA preparation and process of making the same
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
MX9304638A (es) * 1992-07-31 1994-05-31 Neose Pharm Inc Composicion para tratar e inhibir las ulceras gastricas y duodenales.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
GB9313437D0 (en) * 1993-06-30 1993-08-11 Smith Andrew W Pathogenicity sequences in helicobacter pylori
US5679769A (en) * 1994-03-15 1997-10-21 Sloan-Kettering Institute For Cancer Research Synthesis of asparagine-linked glycopeptides on a polymeric solid support
US5708163A (en) * 1994-03-15 1998-01-13 Sloan-Kettering Institute Of Cancer Research Synthesis of the breast tumor-associated antigen defined by monoclonalantibody MBRL and uses thereof
US5625124A (en) * 1994-07-11 1997-04-29 Washington University Animal model for helicobacter pylori infection
FR2724936A1 (fr) * 1994-09-22 1996-03-29 Pasteur Merieux Serums Vacc Recepteur lactoferrine d'helicobacter
US5681736A (en) * 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
CA2202029A1 (en) * 1994-10-05 1996-04-18 John L. Pace Methods for producing enhanced antigenic helicobacter sp. and vaccines comprising same
JP4368944B2 (ja) * 1995-04-21 2009-11-18 シーエスエル、リミテッド 防御用ヘリコバクター抗原
DE19521314A1 (de) * 1995-06-12 1996-12-19 Max Planck Gesellschaft Adhärenzgen aus Helicobacter pylori und davon codiertes Polypeptid
DE19521312A1 (de) * 1995-06-12 1996-12-19 Max Planck Gesellschaft Verfahren zur Identifizierung sekretorischer Gene aus Helicobacter pylori
FR2739623B1 (fr) * 1995-10-04 1997-12-05 Pasteur Merieux Serums Vacc Nouvelle proteine membranaire p76 d'helicobacter pylori
US6410719B1 (en) * 1996-06-10 2002-06-25 Thomas Boren Blood group antigen binding protein and corresponding agents
JP4112011B2 (ja) * 1996-06-10 2008-07-02 トーマス、ボレン Ｈｅｌｉｃｏｂａｃｔｅｒ ｐｙｌｏｒｉアドヘシン結合型抗原
CA2182046A1 (en) * 1996-07-25 1998-01-26 Clifford A. Lingwood Haemophilus adhesin protein
JP3430853B2 (ja) * 1997-04-11 2003-07-28 株式会社ゲン・コーポレーション 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
NZ509127A (en) * 1998-06-19 2004-01-30 Merieux Oravax Use of LT (E. coli) and CT (cholera toxin) for inducing immune responses against helicobacter infection
US6238894B1 (en) * 1998-11-04 2001-05-29 Diane Taylor α1,2 fucosyltransferase
US20020086032A1 (en) * 1999-02-02 2002-07-04 Mahan Michael J. Producing antibodies with attenuated bacteria with altered DNA adenine methylase activity
AU2001258373A1 (en) * 2000-04-27 2001-11-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method for identifying helicobacter antigens
JP2002029999A (ja) * 2000-07-14 2002-01-29 Gen Corp:Kk 消化性潰瘍の予防剤および治療剤
SE0103695D0 (sv) * 2001-11-07 2001-11-07 Thomas Boren A novel non-antibiotic strategy against OGIP infections based on a cereal product
US20050009037A1 (en) * 2002-08-16 2005-01-13 Yung-Fu Chang Helicobacter bizzozeronii outer membrane protein encoding gene and its use in diagnostic and treatment methods
CN101128182B (zh) * 2004-11-25 2011-11-16 荷兰联合利华有限公司 重链和结构域抗体
US8025880B2 (en) * 2007-03-01 2011-09-27 Helicure Ab Immunoglobulin against Helicobacter pylori

Also Published As

Publication number Publication date
US7271251B2 (en) 2007-09-18
AU726429B2 (en) 2000-11-09
EP0909272A1 (de) 1999-04-21
DE69737323T2 (de) 2007-11-08
AU3199997A (en) 1998-01-07
CA2257826A1 (en) 1997-12-18
US6709656B1 (en) 2004-03-23
US20040234529A1 (en) 2004-11-25
JP4112011B2 (ja) 2008-07-02
DE69737323D1 (de) 2007-03-22
NZ333250A (en) 2000-05-26
CA2257826C (en) 2011-11-22
WO1997047646A1 (en) 1997-12-18
ES2281914T3 (es) 2007-10-01
US20080187541A1 (en) 2008-08-07
JP2001503606A (ja) 2001-03-21
EP0909272B1 (de) 2007-02-07

Similar Documents

Publication Publication Date Title
ATE353337T1 (de) Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet
Isogai et al. Specific inhibition of adherence of an oral strain of Bacteroides gingivalis 381 to epithelial cells by monoclonal antibodies against the bacterial fimbriae
RU2432364C2 (ru) ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
UA87093C2 (ru) ГУМАНИЗИРОВАННЫЙ ИММУНОГЛОБУЛИН, КОТОРЫЙ СПЕЦИФИЧЕСКИ СВЯЗЫВАЕТСЯ С БЕТА-АМИЛОИДНЫМ ПЕПТИДОМ (Аβ)
DK0853487T3 (da) Neutraliserende monoklonale antistoffer mod respiratorisk syncytial virus
CA2025597A1 (en) Vaccine against lyme disease
KR950005327A (ko) 임파구 항원 CD2 및 종양 항원을 인식하는 이특이적 트리거(Trigger) 분자
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
HUP9802401A2 (hu) Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1109423T1 (el) Ανθρωπινα μονοκλωνα αντισωματα αντι-ιντελευκινης-5 και μεθοδοι και συνθεσεις που τα περιεχουν
NZ524888A (en) Nucleic acids and proteins from streptococcus groups A & B
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ATE132197T1 (de) Monoklonale antikörper
NO20010412L (no) Anvendelse av borreliacidal(e) epitoper av Borrelia burgdorferi ytre overflateprotein C som vaksine
CN100535116C (zh) 幽门螺杆菌尿素酶b亚单位b细胞抗原表位多肽与应用
Ortega‐Pierres et al. Workshop on a detailed characterization of Trichinella spiralis antigens: a platform for future studies on antigens and antibodies to this parasite
SE9401460D0 (sv) Antigen/antibody specificity exhanger
CA2457362A1 (en) Human monoclonal rabies virus neutralizing antibodies, and methods for making and using the same
CA2525657A1 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of serotype iats o6 of pseudomonas aeruginosa
CA2597701A1 (en) Human monoclonal antibody specific for lipopolysaccharides (lps) of the pseudomonas aeruginosa iats o11 serotype
DK0474645T3 (da) Proteinkompleks
Bailey et al. Production of murine monoclonal antibodies to the major axial filament polypeptide of Treponema pallidum
WO1995020658A3 (en) Diagnosis and treatment of infections due to streptococci and enterococci
King Monoclonal antibody studies on rabies-related viruses

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0909272

Country of ref document: EP